Literature DB >> 20545388

Contingency management and levodopa-carbidopa for cocaine treatment: a comparison of three behavioral targets.

Joy M Schmitz1, Jan A Lindsay, Angela L Stotts, Charles E Green, F Gerard Moeller.   

Abstract

New data support use of levodopa pharmacotherapy with behavioral contingency management (CM) as one efficacious combination in cocaine dependence disorder treatment. A potential mechanism of the combined treatment effects may be related to dopamine-induced enhancement of the saliency of contingently delivered reinforcers. Evidence to support this mechanism was sought by evaluating levodopa-enhancing effects across distinct CM conditions that varied in behavioral targets. A total of 136 treatment-seeking, cocaine dependent subjects participated in this 12-week, randomized, placebo-controlled trial of levodopa (vs. placebo) administered in combination with one of three behavioral CM conditions. In the CM-URINE condition, subjects received cash-valued vouchers contingent on cocaine-negative urine toxicology results. In the CM-ATTEND condition, the same voucher schedule was contingent on attending thrice weekly clinic visits. In the CM-MEDICATION condition, the same voucher schedule was contingent on Medication Event Monitoring Systems- and riboflavin-based evidence of pill-taking behavior. Primary outcomes associated with each CM target behavior were analyzed using generalized linear mixed models for repeated outcomes. CM responding in the CM-ATTEND and CM-MEDICATION conditions showed orderly effects, with each condition producing corresponding changes in targeted behaviors, regardless of medication condition. In contrast, CM responding in the CM-URINE condition was moderated by medication, with levodopa-treated subjects more likely to submit cocaine-negative urines. These findings specify the optimal target behavior for CM when used in combination with levodopa pharmacotherapy.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20545388      PMCID: PMC3164487          DOI: 10.1037/a0019195

Source DB:  PubMed          Journal:  Exp Clin Psychopharmacol        ISSN: 1064-1297            Impact factor:   3.157


  27 in total

1.  Incentive program decreases no-shows in nontreatment substance abuse research.

Authors:  Alisha R Pollastri; Melyssa L Pokrywa; Stephen J Walsh; Henry R Kranzler; Joel Gelernter
Journal:  Exp Clin Psychopharmacol       Date:  2005-11       Impact factor: 3.157

Review 2.  A meta-analysis of voucher-based reinforcement therapy for substance use disorders.

Authors:  Jennifer Plebani Lussier; Sarah H Heil; Joan A Mongeon; Gary J Badger; Stephen T Higgins
Journal:  Addiction       Date:  2006-02       Impact factor: 6.526

Review 3.  Contingency management for treatment of substance use disorders: a meta-analysis.

Authors:  Michael Prendergast; Deborah Podus; John Finney; Lisa Greenwell; John Roll
Journal:  Addiction       Date:  2006-11       Impact factor: 6.526

4.  Can replacement therapy work in the treatment of cocaine dependence? And what are we replacing anyway?

Authors:  Frank J Vocci
Journal:  Addiction       Date:  2007-12       Impact factor: 6.526

5.  A perfect platform: combining contingency management with medications for drug abuse.

Authors:  Kathleen M Carroll; Bruce J Rounsaville
Journal:  Am J Drug Alcohol Abuse       Date:  2007       Impact factor: 3.829

6.  Measurement of compliance with naltrexone in the treatment of alcohol dependence: research and clinical implications.

Authors:  K Namkoong; C K Farren; P G O'Connor; S S O'Malley
Journal:  J Clin Psychiatry       Date:  1999-07       Impact factor: 4.384

7.  Voucher reinforcement improves medication adherence in HIV-positive methadone patients: a randomized trial.

Authors:  James L Sorensen; Nancy A Haug; Kevin L Delucchi; Valerie Gruber; Evan Kletter; Steven L Batki; Jacqueline P Tulsky; Paul Barnett; Sharon Hall
Journal:  Drug Alcohol Depend       Date:  2006-10-23       Impact factor: 4.492

8.  Shaping smoking cessation using percentile schedules.

Authors:  R J Lamb; Andrew R Morral; Kimberly C Kirby; M Y Iguchi; G Galbicka
Journal:  Drug Alcohol Depend       Date:  2004-12-07       Impact factor: 4.492

9.  Citalopram combined with behavioral therapy reduces cocaine use: a double-blind, placebo-controlled trial.

Authors:  F Gerard Moeller; Joy M Schmitz; Joel L Steinberg; Charles M Green; Christopher Reist; Lingo Y Lai; Alan C Swann; John Grabowski
Journal:  Am J Drug Alcohol Abuse       Date:  2007       Impact factor: 3.829

10.  Randomized trial of contingent prizes versus vouchers in cocaine-using methadone patients.

Authors:  Nancy M Petry; Sheila M Alessi; Tressa Hanson; Sean Sierra
Journal:  J Consult Clin Psychol       Date:  2007-12
View more
  15 in total

Review 1.  Psychostimulant treatment of cocaine dependence.

Authors:  John J Mariani; Frances R Levin
Journal:  Psychiatr Clin North Am       Date:  2012-04-26

Review 2.  Dopamine ups and downs in vulnerability to addictions: a neurodevelopmental model.

Authors:  Marco Leyton; Paul Vezina
Journal:  Trends Pharmacol Sci       Date:  2014-04-30       Impact factor: 14.819

Review 3.  New Directions in Medication-Facilitated Behavioral Treatment for Substance Use Disorders.

Authors:  Elias Dakwar; Edward V Nunes
Journal:  Curr Psychiatry Rep       Date:  2016-07       Impact factor: 5.285

4.  Evaluation of buspirone for relapse-prevention in adults with cocaine dependence: an efficacy trial conducted in the real world.

Authors:  Theresa Winhusen; Kathleen T Brady; Maxine Stitzer; George Woody; Robert Lindblad; Frankie Kropp; Gregory Brigham; David Liu; Steven Sparenborg; Gaurav Sharma; Paul Vanveldhuisen; Bryon Adinoff; Eugene Somoza
Journal:  Contemp Clin Trials       Date:  2012-05-19       Impact factor: 2.226

5.  Anhedonia Is Associated with Poorer Outcomes in Contingency Management for Cocaine Use Disorder.

Authors:  Margaret C Wardle; Jessica N Vincent; Robert Suchting; Charles E Green; Scott D Lane; Joy M Schmitz
Journal:  J Subst Abuse Treat       Date:  2016-09-09

6.  Expectancy-Related Changes in Dopaminergic Error Signals Are Impaired by Cocaine Self-Administration.

Authors:  Yuji K Takahashi; Thomas A Stalnaker; Yasmin Marrero-Garcia; Ray M Rada; Geoffrey Schoenbaum
Journal:  Neuron       Date:  2019-01-16       Impact factor: 17.173

Review 7.  Combination pharmacotherapies for stimulant use disorder: a review of clinical findings and recommendations for future research.

Authors:  William W Stoops; Craig R Rush
Journal:  Expert Rev Clin Pharmacol       Date:  2014-04-09       Impact factor: 5.045

8.  Atomoxetine does not alter cocaine use in cocaine dependent individuals: double blind randomized trial.

Authors:  Sharon L Walsh; Lisa S Middleton; Conrad J Wong; Paul A Nuzzo; Charles L Campbell; Craig R Rush; Michelle R Lofwall
Journal:  Drug Alcohol Depend       Date:  2012-11-28       Impact factor: 4.492

9.  A two-phased screening paradigm for evaluating candidate medications for cocaine cessation or relapse prevention: modafinil, levodopa-carbidopa, naltrexone.

Authors:  Joy M Schmitz; Charles E Green; Angela L Stotts; Jan A Lindsay; Nuvan S Rathnayaka; John Grabowski; F Gerard Moeller
Journal:  Drug Alcohol Depend       Date:  2014-01-03       Impact factor: 4.492

10.  Measuring Outcome in the Treatment of Cocaine Dependence.

Authors:  Paul Crits-Christoph; Robert Gallop; Mary Beth Connolly Gibbons; Jaclyn S Sadicario; George Woody
Journal:  J Alcohol Drug Depend       Date:  2013-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.